Tag Archives: api

7 Steps To The Launching Of A National Debate On The Realities Of Stock Investing

By Rob Bennett Step One: The Buy-and-Holders Accept That a Debate Is Inevitable. This is a turf battle. Eugene Fama and Robert Shiller have both won Nobel prizes for saying opposite things about how stock investing works. It’s not possible that both are right. The natural thing would have been for the debate to have been launched in 1981, when Shiller published his “revolutionary” (his word) research findings. Things got held up because there is so much money to be made in this field, and by the time Shiller published his research, thousands of people had built careers promoting Buy-and-Hold strategies. These people were naturally not too excited about the idea of acknowledging that they had been giving bad advice for a long time. The reality is that sooner or later, they are going to have to at least acknowledge that possibility. A Nobel prize cannot be denied. And, if Shiller is right, the promotion of Buy-and-Hold strategies caused an economic crises. This affects everyone. So, the debate has to come. Once that is widely recognized, the question changes from whether or not to have the debate to how to proceed with the important business of launching it. Step Two: Industry Leaders Recognize How Much Money There Is to Be Made by Moving Forward. I often hear a cynical response when I make the case for the launching of a national debate. People say that there is too much money made promoting Buy-and-Hold for the industry to permit a debate that might discredit the strategy. I don’t think that’s right. Valuation-Informed Indexing reduces risk dramatically. Millions of middle-class people resist the lure of stocks because they are turned off by the idea of taking on too much risk with their retirement money. A transition to the Shiller model would increase profits for those in the stock-selling industry, not diminish them. The problem, for many years, has been that profits were good enough as a result of the huge bull market, and so, there was a feeling that there was no cause to rock the boat. The next price crash will change that. After prices fall hard again, the industry will be feeling the pinch and will go looking for ways to restore public confidence in the market. That’s when people will see that the model of the future has been available to us for 35 years – it’s just been a question of us developing an interest in taking advantage of the opportunity. Step Three: Jack Bogle Says “I’m Not Entirely Sure” Whether Fama or Shiller is Right. The debate has been delayed because the Buy-and-Hold Model was established first, and getting investing right is so important that the Buy-and-Holders have thus far not been able to acknowledge even the possibility of their having made a mistake. That changes on the day when Bogle says the words “I’m” and “Not” and “Sure” in a public place and his words are written up on the front page of the New York Times . Everyone who works in this field would interpret those words as giving them permission to talk openly about the case against Buy-and-Hold. Once there are people speaking openly, clearly and firmly on both sides of the story, we will all be engaged in an amazing learning experience. Step Four: Behavioral Finance Experts Seek to Distinguish Themselves By Drawing Sharp Contrasts Between Their Advice on Strategic Questions and the Advice Offered by the Buy-and-Holders. Behavioral Finance has been a growing field for many years. But it has had little impact in the practical realm, because the Behavioral Finance experts have shied away from showing how a model that considers the effect of human psychology on investing choices leads to very different advice on strategic questions (particularly, asset allocation questions). For so long as Buy-and-Hold has remained dominant, it has seemed “rude” to point out that the Buy-and-Hold advice on just about every question is dangerous if Shiller is right that valuations affect long-term returns and that risk is thus not static, but variable. Once the floodgates are opened by Bogle’s historic speech, each of the Behavioral Finance experts will tap into a healthy competitive instinct to distinguish himself or herself by showing how different his or her advice is from the conventional Buy-and-Hold advice. We will see 35 years of insights developed and explained and promoted and explored in the space of a few years. Exciting times! Step Five: Thought Leaders Recognize the Need to Help the Buy-and-Holders Save Face. We need to see a battle of ideas, not a battle of personalities. We want the Buy-and-Holders working with us, not against us. The Buy-and-Holders built the foundation on which Valuation-Informed Indexing is built. It would be as crazy for us to come to see them as enemies once the debate is launched as it has been for them to see us as enemies during the decades in which it has been delayed. Wise heads will prevail. We will see that we are all in this together. As a result, things will move ahead at a quick pace once things begin moving ahead. The Buy-and-Holders have a lot to contribute, and they will do so as long as we are careful to acknowledge their many genuine achievements. Step Six: The Political Implications of Shiller’s Breakthrough Come to Be More Widely Appreciated. It was the promotion of Buy-and-Hold strategies that caused the economic crisis (by encouraging stock prices to soar to insanely dangerous levels, and then by causing the economy to lose trillions of dollars of buying power when the bubble popped). The economic crisis affects all of us, not just the investing industry and not just those who buy stocks. The debate will go into high gear when it becomes widely understood that we all have a stake in ensuring that we all have access to sound, responsible and research-backed investing advice. The stock-selling industry has been dragging its feet for a long time. But this is bigger than the stock-selling industry. Step Seven: Outsiders Flood into the Stock-Selling Industry. The launching of the debate need not be perceived as a threat to those currently working in the field and promoting Buy-and-Hold strategies. But it will speed things up when initial discussion of the new model shows the need for the industry to welcome new types of experts. We will be seeing a transition from a focus on math-based skills to a focus on psychology-based skills. The new blood will bring the field alive (but we are, of course, always going to need lots of people with math-based skills in this field). Disclosure: None.

Buffett’s 5 Business Lessons

Originally published on Mar 30, 2016 What by Buffett’s standards is a good business? A good business according to Warren Buffett is a business that earns a high rate of return on tangible assets. The very best businesses are ones that earn high rates of return on tangible assets and grows. You can turn a good business into a bad investment by buying at too high of a price. Buffett’s statements above alludes to businesses that do not require a lot of capital investment such as the Van Tuyl Automotive car dealership business he purchased in 2014. Whereby in the dealership business, you can lease the real estate, arrange the floor plan, and sell a lot of volume with narrow margins and still manage a high return on capital. Years ago, car dealerships were many and across the U.S., there were about 30,000. Now that amount is a little more than half and on average each dealer does greater volume than ever before. However, I will say that his investment in BNSF Railway is quite the opposite and is a highly capital intensive business. Click to enlarge Are the big banks good business and are they still as good of a business prior to the 2008 crisis? Banks earn on assets not on their net worth. Since 2008, the government now requires banks to have more net worth for each dollar of asset. Meaning that their earnings on net worth will go down. Banks are required to have more net worth than before to make the “same” amount of money. In general, they are great business because they can borrow money cheaply. Think of your deposits sitting in a Wells Fargo (NYSE: WFC ) or Bank of America (NYSE: BAC ) checking or savings account. What interest rates are those paying out? More than likely it is something to the tune of less than 0.10% annual percentage yield. Banks turn around and lend that money out at interest rates at least 20 to 30 times that. “Keep the business if you expect the company to do well in the future versus the price now compared to other opportunities you might think you know equally well.” In 2014, Buffett still believed that most stocks were being priced at a range of reasonableness. There has only been five times in Buffett’s lifetime that he recalls whereby businesses were either priced too expensive or very cheap. There is no way to pinpoint exactly where those peaks and troughs are, but he believe he can make a call on either end of the spectrum every 5-10 years. Overall, buy good businesses at reasonable prices and you’ll make money. Another piece of advice? Buy stock in a business so good that an idiot can run it because one day an idiot will. Forget about what is happening in the United States about the Fed and economy. In the long run, the American system works and unleashes human potential, which will bring value to the economy. Buy a business because of what is happening in the business not because of what you think political effects have on the business or doesn’t have on the business. When do you throw in the towel on an investment or business? If you have a bad manager with bad results, you can sometimes change the manager and get good results. But if you have a bad business and a good manager, most of the time, you can’t get better with a better manager. Some businesses are just plain tough and the bad economics almost always trumps good management. Buffett loves it when the things they buy go down in value. When you go to the grocery store and find something cheaper today than yesterday you are elated. But for some reason with a stock, people tend to hold on to it and sell when it gets to what they paid for it. People have a tendency to justify holding on to positions. The stocks don’t care what you bought them for. You are nothing to the stock, but the stock is everything to you. How do you know when to sell a stock or rearrange your portfolio? When you can get can more for your money somewhere else. Prices change constantly and valuations shift daily. Today, you can rearrange your business empire at virtually no cost. But people can use that to a disadvantage as well by trading too much. Keep the business if you expect the company to do well in the future versus the price now compared to other opportunities you might think you know equally well.

Healthcare Mutual Funds To Bounce Back After Q1 Debacle: 5 Picks

The healthcare space was mostly out of favor in the first quarter following Democratic Presidential Candidate, Hillary Clinton’s allegation on “price gouging.” The massive decline in Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX ) shares also had an adverse impact on biotech stocks, eventually dragging the healthcare sector down. Healthcare mutual funds weren’t spared as the category turned out to be the worst performer in the first quarter. Foremost funds from the healthcare space failed to end in positive territory during the period. Despite this hiccup, investors shouldn’t be demoralized as the long term bodes well for such funds. The healthcare sector is poised to gain from an ageing population both at home and abroad. And with an increase in mergers, and innovative product pipelines and approvals, it’s just a matter of time before the sector bounces back. Not to forget that biotech stocks have already rebounded in the past few days after being torn apart in the first three months of the year. Banking on this optimism, it will be prudent to invest in healthcare funds that have given solid returns over a long period of time and also boast strong fundamentals. (Read: 3 Healthcare Funds to Buy on Biotech Rebound ) Healthcare Losing Ground in Q1 It’s been an awful first quarter for the healthcare sector. Political scrutiny about drug prices took a toll on healthcare stocks. Healthcare Equity Funds nosedived 13.28% during the first quarter, according to Morningstar. Among the worst performing drug makers were Mallinckrodt Public Limited Company (NYSE: MNK ), Horizon Pharma plc (NASDAQ: HZNP ) and Endo International plc (NASDAQ: ENDP ), whose shares plunged 17.9%, 21.4% and 54%, respectively, in the first quarter. If you think that was bad, then biotechs had it even worse. The iShares NASDAQ Biotechnology Index plummeted almost 23% in the first quarter. The Valeant Pharmaceuticals disaster was also responsible for the significant underperformance. U.S. lawmakers investigating Valeant’s pricing practices, accusations about accounting irregularities and delay in filing annual reports practically ruined the company. In the first quarter alone, Valeant’s shares plummeted 36.8%. With the new tax inversion rules the pain seems to have intensified. According to the U.S. Treasury Department and Internal Revenue Service, the rule bars U.S. companies from undertaking inversion transactions if they have done so in the past three years. These inversion deals were a ploy for U.S. drug companies to dodge tax bills by relocating their headquarters abroad. On the earnings front, things are also looking gloomy. First-quarter earnings from the healthcare sector are anticipated to grow a meager 0.6% from the year-ago level compared with 9.3% growth witnessed in the previous quarter. (Read: Previewing the Q1 Earnings Season ) Tailwinds are Strong Even though healthcare witnessed a dismal first quarter, the sector is positioned to grow in the future thanks to an ageing American population. There are about 77 million U.S. baby boomers, which is quite a significant number. An ageing population bodes well for the healthcare sector as they require more medical attention. Along with it, an ageing China also provides long-term opportunities for both U.S. pharmaceutical and medical technology companies. The need to trim costs and tap growth opportunities are driving healthcare firms into mergers and acquisitions (M&A). Additionally, the Fed’s dovish outlook to proceed cautiously on hiking rates is also expected to boost M&A deals. Also, the first FDA-approved biosimilar, Zarxio, hit the market last year. Biotech companies are now vying to enter this high revenue generating space. Several other products such as Imlygic, Ibrance, Strensiq, Genvoya and, PCSK9 inhibitors, Praluent and Repatha also got approved. This in turn is expected to help companies from the healthcare space to generate steady revenues. Thanks to the mandated healthcare coverage in the U.S., more Americans are seeking treatment, which is also a net positive for healthcare firms. 5 Healthcare Mutual Funds to Invest In As discussed above, these tailwinds may collectively act as growth facilitators and help the healthcare sector overcome the drubbing it took in the first quarter. In case of inversion rules, healthcare companies will continue to seek creative ways to relocate their tax residence to avoid paying the lofty taxes at home, as per the Treasury Secretary Jacob J. Lew. Since the long run holds good for the healthcare sector, it will be wise to buy mutual funds associated with the sector. These funds have yielded positive returns for a long time despite being in the red in the first quarter. Moreover, these funds are fundamentally solid, which will eventually help them gain in the future as well. We have selected five healthcare mutual funds that have impressive 3-year and 5-year annualized returns and carry a Zacks Mutual Fund Rank #1 (Strong Buy) or #2 (Buy). These funds also possess a relatively low expense ratio and have minimum initial investment within $5000. T. Rowe Price Health Sciences Fund (MUTF: PRHSX ) invests a large portion of its assets in companies engaged in the development and distribution of health care products. PRHSX’s 3-year and 5-year annualized returns are 19.7% and 21.1%, respectively. Annual expense ratio of 0.76% is lower than the category average of 1.35%. PRHSX has a Zacks Mutual Fund Rank #1. Fidelity Select Health Care Portfolio (MUTF: FSPHX ) invests a major portion of its assets in companies involved in the manufacture and sale of products used in connection with health care. FSPHX’s 3-year and 5-year annualized returns are 19.2% and 18.8%, respectively. Annual expense ratio of 0.74% is lower than the category average of 1.35%. FSPHX has a Zacks Mutual Fund Rank #2. Hartford Healthcare Fund A (MUTF: HGHAX ) invests the majority of its assets in the equity securities of health care-related companies worldwide. HGHAX’s 3-year and 5-year annualized returns are 17.3% and 17.7%, respectively. Annual expense ratio of 1.28% is lower than the category average of 1.35%. HGHAX has a Zacks Mutual Fund Rank #2. Live Oak Health Sciences Fund (MUTF: LOGSX ) invests a large portion of its assets in equity securities of health sciences companies. LOGSX’s 3-year and 5-year annualized returns are 16.1% and 15.7%, respectively. Annual expense ratio of 1.08% is lower than the category average of 1.35%. LOGSX has a Zacks Mutual Fund Rank #2. Fidelity Select Biotechnology Portfolio (MUTF: FBIOX ) invests the majority of its assets in companies engaged in the manufacture and distribution of various biotechnological products. FBIOX’s 3-year and 5-year annualized returns are 16.1% and 23.7%, respectively. Annual expense ratio of 0.74% is lower than the category average of 1.35%. FBIOX has a Zacks Mutual Fund Rank #2. Link to the original post on Zacks.com